NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹433 Cr | ₹356 Cr | ₹287 Cr | ₹277 Cr | ₹207 Cr |
What is the latest Total Liabilities ratio of NGL FINECHEM ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹433 Cr |
| Mar2024 | ₹356 Cr |
| Mar2023 | ₹287 Cr |
| Mar2022 | ₹277 Cr |
| Mar2021 | ₹207 Cr |
How is Total Liabilities of NGL FINECHEM Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹433 Cr | 21.90 | |
| Mar2024 | ₹356 Cr | 23.85 | |
| Mar2023 | ₹287 Cr | 3.67 | |
| Mar2022 | ₹277 Cr | 33.53 | |
| Mar2021 | ₹207 Cr | - | |
Compare Total Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,351.2 Cr | 24.5% | 43.8% | 37.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,615.0 Cr | 4% | -4.9% | -2.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,943.0 Cr | 1.1% | -9.3% | 9.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹133,336.0 Cr | -1.3% | -3.7% | 24% | Stock Analytics | |
| CIPLA | ₹107,499.0 Cr | 1.5% | -9.3% | -7.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,590.0 Cr | 5% | -0.1% | 3.3% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 24.5% |
43.8% |
37.7% |
| SENSEX | 3.5% |
-1.7% |
7.8% |
You may also like the below Video Courses